메뉴 건너뛰기




Volumn 3, Issue 3, 2016, Pages

Cefepime therapy for cefepime- susceptible extended-spectrum β-lactamase-producing enterobacteriaceae bacteremia

Author keywords

Bacteremia; Carbapenem; Cefepime; ESBL; Multidrug resistant organisms

Indexed keywords

CARBAPENEM; CEFEPIME; CILASTATIN PLUS IMIPENEM; ERTAPENEM; MEROPENEM;

EID: 85015839849     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofw132     Document Type: Article
Times cited : (57)

References (17)
  • 2
    • 85015833005 scopus 로고    scopus 로고
    • Version 1.1. Accessed 1 July 2016
    • EUCAST: The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Sone Diameters. Version 1.1. Available at: http://www.eucast.org. Accessed 1 July 2016.
    • Breakpoint Tables for Interpretation of MICs and Sone Diameters
  • 3
    • 84863730126 scopus 로고    scopus 로고
    • Extended-spectrum beta-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests
    • Marchaim D, Sunkara B, Lephart PR, et al. Extended-spectrum beta-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests. Infect Control Hosp Epidemiol 2012; 33:853-5.
    • (2012) Infect Control Hosp Epidemiol , vol.33 , pp. 853-855
    • Marchaim, D.1    Sunkara, B.2    Lephart, P.R.3
  • 4
    • 77957866989 scopus 로고    scopus 로고
    • High frequency of beta-lactam susceptibility in CTX-M-type extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations
    • de Oliveira KR, de Freitas AL, Willers DM, et al. High frequency of beta-lactam susceptibility in CTX-M-type extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations. J Antimicrob Chemother 2010; 65:2481-3.
    • (2010) J Antimicrob Chemother , vol.65 , pp. 2481-2483
    • de Oliveira, K.R.1    de Freitas, A.L.2    Willers, D.M.3
  • 5
    • 29144493229 scopus 로고    scopus 로고
    • Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase-and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004)
    • Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase-and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis 2005; 53:257-64.
    • (2005) Diagn Microbiol Infect Dis , vol.53 , pp. 257-264
    • Goossens, H.1    Grabein, B.2
  • 6
    • 84873021014 scopus 로고    scopus 로고
    • Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamaseproducing Enterobacteriaceae: MIC matters
    • Lee NY, Lee CC, Huang WH, et al. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamaseproducing Enterobacteriaceae: MIC matters. Clin Infect Dis 2013; 56:488-95.
    • (2013) Clin Infect Dis , vol.56 , pp. 488-495
    • Lee, N.Y.1    Lee, C.C.2    Huang, W.H.3
  • 7
    • 84862573595 scopus 로고    scopus 로고
    • Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-betalactamase-producing Klebsiella pneumoniae and Escherichia coli
    • Chopra T, Marchaim D, Veltman J, et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-betalactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 2012; 56:3936-42.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 3936-3942
    • Chopra, T.1    Marchaim, D.2    Veltman, J.3
  • 8
    • 0035003640 scopus 로고    scopus 로고
    • Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory
    • Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206-12.
    • (2001) J Clin Microbiol , vol.39 , pp. 2206-2212
    • Paterson, D.L.1    Ko, W.C.2    Von Gottberg, A.3
  • 9
    • 3042706689 scopus 로고    scopus 로고
    • Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum betalactamases
    • Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum betalactamases. Clin Infect Dis 2004; 39:31-7.
    • (2004) Clin Infect Dis , vol.39 , pp. 31-37
    • Paterson, D.L.1    Ko, W.C.2    Von Gottberg, A.3
  • 10
    • 10744230588 scopus 로고    scopus 로고
    • Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study
    • Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47:3442-7.
    • (2003) Antimicrob Agents Chemother , vol.47 , pp. 3442-3447
    • Zanetti, G.1    Bally, F.2    Greub, G.3
  • 11
    • 33751566651 scopus 로고    scopus 로고
    • Bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge
    • Rodriguez-Bano J, Navarro MD, Romero L, et al. Bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43:1407-14.
    • (2006) Clin Infect Dis , vol.43 , pp. 1407-1414
    • Rodriguez-Bano, J.1    Navarro, M.D.2    Romero, L.3
  • 12
    • 84869484115 scopus 로고    scopus 로고
    • Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis
    • Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012; 67:2793-803.
    • (2012) J Antimicrob Chemother , vol.67 , pp. 2793-2803
    • Vardakas, K.Z.1    Tansarli, G.S.2    Rafailidis, P.I.3    Falagas, M.E.4
  • 13
    • 0141531017 scopus 로고    scopus 로고
    • Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period
    • Burgess DS, Hall RG II, Lewis JS II, et al. Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy 2003; 23:1232-7.
    • (2003) Pharmacotherapy , vol.23 , pp. 1232-1237
    • Burgess, D.S.1    Hall, R.G.2    Lewis, J.S.3
  • 14
    • 0035189967 scopus 로고    scopus 로고
    • Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae
    • Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45:3548-54.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 3548-3554
    • Thomson, K.S.1    Moland, E.S.2
  • 15
    • 0035086683 scopus 로고    scopus 로고
    • In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain
    • Szabo D, Mathe A, Filetoth Z, et al. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain. Antimicrob Agents Chemother 2001; 45:1287-91.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 1287-1291
    • Szabo, D.1    Mathe, A.2    Filetoth, Z.3
  • 16
    • 0030956601 scopus 로고    scopus 로고
    • Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae
    • Thauvin-Eliopoulos C, Tripodi MF, Moellering RC Jr, Eliopoulos GM. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1997; 41:1053-7.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 1053-1057
    • Thauvin-Eliopoulos, C.1    Tripodi, M.F.2    Moellering, R.C.3    Eliopoulos, G.M.4
  • 17
    • 34547224444 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units
    • Roos JF, Bulitta J, Lipman J, Kirkpatrick CM. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 2006; 58:987-93.
    • (2006) J Antimicrob Chemother , vol.58 , pp. 987-993
    • Roos, J.F.1    Bulitta, J.2    Lipman, J.3    Kirkpatrick, C.M.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.